Retrospective Study of Genetic Risk Factors for Osteosarcoma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Children's Oncology Group
- Enrollment
- 1,000
- Locations
- 1
- Primary Endpoint
- SNPs associated with OS
Study Overview
Brief Summary
This research trial studies blood samples from patients with osteosarcoma. Studying the genes found in samples of blood from patients with osteosarcoma may help doctors identify biomarkers related to the disease.
Detailed Description
PRIMARY OBJECTIVE:
I. Conduct a large-scale candidate gene association study in osteosarcoma (OS) using cases from the national Children's Oncology Group (COG) OS biology study (P9851 and successor study AOST06B1).
SECONDARY OBJECTIVES:
I. Conduct a genome-wide association study (GWAS) of OS. II. Fine-map genomic regions associated with OS to identify putative functional loci.
III. Conduct whole-exome sequencing of germline OS deoxyribonucleic acid (DNA) samples.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Blood samples collected from clinical trials COG-P9851 and COG-AOST06B1
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
SNPs associated with OS
Time Frame: Baseline
Logistic regression will be used to estimate odds ratios and 95% confidence intervals for the association between each SNP and OS under co-dominant, dominant and recessive genetic models. Stratified analyses will be conducted to examine sex, tumor subtype and outcome differences.
Gene-gene interactions
Time Frame: Baseline
Assessed using a multiplicative model. Haplotypes will be constructed using both Bayesian and expectation-maximization algorithms. Differences between cases and controls will be evaluated with HaploStats which uses haplotype posterior probabilities as weights to update the regression coefficients in an iterative manner.
Hardy-Weinberg equilibrium on all SNPs
Time Frame: Baseline
Determined on all SNPs by chi-square tests.
Whole-exome variant loci
Time Frame: Baseline
Annotation and filtering of each whole-exome variant locus will be performed using a custom software pipeline. Variants in \>= 2 OS cases will be validated, and then subsequently replicated in additional OS cases (samples previously received for the GWAS from international collaborators). Variants will also be evaluated for presence in known biologically plausible pathways and genes.
Survival outcomes
Time Frame: Baseline
Kaplan-Meier survival curves will be used to determine outcome relative to genotype.
Secondary Outcomes
No secondary outcomes reported